Bee venom effects on ubiquitin proteasome system in hSOD1-expressing NSC34 motor neuron cells by unknown
Kim et al. BMC Complementary and Alternative Medicine 2013, 13:179
http://www.biomedcentral.com/1472-6882/13/179RESEARCH ARTICLE Open AccessBee venom effects on ubiquitin proteasome
system in hSOD1G85R-expressing NSC34 motor
neuron cells
Seon Hwy Kim1, So Young Jung1, Kang-Woo Lee1, Sun Hwa Lee1, MuDan Cai1, Sun-Mi Choi2 and Eun Jin Yang1*Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that results from a progressive loss
of motor neurons. Familial ALS (fALS) is caused by missense mutations in Cu, Zn-superoxide dismutase 1 (SOD1)
that frequently result in the accumulation of mutant protein aggregates that are associated with impairments in the
ubiquitin-proteasome system (UPS). UPS impairment has been implicated in many neurological disorders. Bee
venom (BV) extracted from honey bees has been used as a traditional medicine for treating inflammatory diseases
and has been shown to attenuate the neuroinflammatory events that occur in a symptomatic ALS animal model.
Methods: NSC34 cells were transiently transfected with a WT or G85R hSOD1-GFP construct for 24 hrs and then
stimulated with 2.5 μg/ml BV for 24 hrs. To determine whether a SOD1 mutation affects UPS function in NSC34
cells, we examined proteasome activity and performed western blotting and immunofluorescence using specific
antibodies, such as anti-misfolded SOD1, anti-ubiquitin, anti-GRP78, anti-LC3, and anti-ISG15 antibodies.
Results: We found that GFP-hSOD1G85R overexpression induced SOD1 inclusions and reduced proteasome activity
compared with the overexpression of GFP alone in NSC34 motor neuronal cells. In addition, we also observed that
BV treatment restored proteasome activity and reduced the accumulation of ubiquitinated and misfolded SOD1 in
GFP-hSOD1G85R-overexpressing NSC34 motor neuronal cells. However, BV treatment did not activate the autophagic
pathway in these cells.
Conclusion: Our findings suggest that BV may rescue the impairment of the UPS in ALS models.
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NSC34 motor neuronal cellsBackground
Amyotrophic lateral sclerosis (ALS) is the most common
adult-onset motor neurodegenerative disease. ALS is
characterized by a progressive loss of motor neurons in
the spinal cord, brain stem and motor cortex that leads
to the rapid and progressive atrophy of skeletal muscles.
Although the majority of ALS cases are sporadic (sALS),
5–10% are inherited autosomal-dominant cases (fALS)
that result from the generation of misfolded or abnormal
proteins [1]. Among fALS cases, approximately 15–20%
involve missense mutations in the gene encoding copper/* Correspondence: yej4823@hanmail.net
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reproduction in any medium, provided the orzinc superoxide dismutase (SOD1). Although many stud-
ies have demonstrated that oxidative stress, mitochon-
drial degeneration, cytoskeletal alterations, and growth
factor abnormalities occur in ALS models, the mechan-
ism of pathogenicity in ALS is completely unknown. One
hypothesis suggests that mutated and misfolded SOD1 is
a critical factor, and these proteins are believed to play a
major role in motor neuron dysfunction and death in
ALS [2].
Abnormal and misfolded proteins are degraded by the
ubiquitin-proteasome system (UPS) and autophagy-
lysosome pathway (ALP). Impairments in these systems
may lead to the accumulation and aggregation of
misfolded proteins, resulting in cellular toxicity and death.
Wild-type SOD1 and the A4V, G85R and G93A mutant. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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agy degradation pathways [3]. The A4V, G85R and G93A
mutant SOD1 proteins are more easily misfolded and
more unstable than wild-type SOD1 [3-5]. For example,
inhibiting proteasomes in culture using epoxomicin
induced the accumulation of mutant hSOD1G93A [3].
Furthermore, misfolded or ubiquitinated SOD1 is found
in the motor neurons of a transgenic mouse model of
ALS [6]. The autophagic degradation of wild-type and
mutant SOD1, however, was blocked in cultures treated
with 3-MA, an inhibitor of macroautophagy, and ammo-
nium chloride, an inhibitor of lysosomal proteolysis,
suggesting that autophagy contributes to the clearance of
wild-type and mutant SOD1 [3,7]. In vivo studies have
demonstrated that macroautophagy plays an important
role in preventing neurodegeneration in mice [8,9]. In
addition to the UPS, mutant SOD1 is also cleared by
autophagy. This finding supports the hypothesis that the
impaired autophagic degradation of mutant SOD1 is an
important mechanism leading to neurodegeneration in
ALS and that the misfolding of mutant SOD1 is a critical
feature of ALS pathology. Therefore, reducing the accu-
mulation of misfolded or aggregated SOD1 may be of
therapeutic value for treating ALS.
Bee venom (BV) extracted from honey bees has been
used in traditional oriental medicine. BV contains a variety
of peptides, including melittin, apamin and adolapin, as
well as enzymes and biogenic active amines. Recent stud-
ies have reported that BV has anti-nociceptive [10,11] and
anti-inflammatory [12,13] effects. It has been used to treat
disease models for rheumatoid arthritis [11] and cancer
[14] as well as neurodegenerative disease models, such as
Alzheimer’s disease (AD) [15], Parkinson’s disease (PD)
[16], and ALS [17].
In this study, we investigated the effects of BV on
proteasome activity in cells expressing the mutant
hSOD1G85R gene and demonstrated that BV restored
proteasome activity, resulting in a reduction in ubi-
quitinated mutant hSOD1G85R in NSC34 motor neurons.
Furthermore, we showed that BV treatment significantly
reduced the amount of misfolded SOD1 in hSOD1G85R-
expressing NSC34 cells. The findings of this study sug-
gest that BV treatment may be able to eliminate the cell
toxicity induced by ubiquitinated or misfolded mutant
hSOD1G85R in motor neurons and restore proteasome
activity in ALS.Methods
Plasmid constructs
The pcDNA3-GFP expression plasmid containing GFP-
tagged wild-type or G85R-mutant SOD1 were kindly do-
nated by Yoshiaki Furukawa (RIKEN Brain Science
Institute).Cell culture and transfections
The motor neuron cell line NSC34 was purchased from
Cellutions Biosystems Inc. (Toronto, ON, Canada) and
maintained inDulbecco’smodified Eagle’smedium (DMEM)
supplemented with 10% fetal bovine serum (Gibco, NY,
USA), 100 U/ml penicillin (Gibco, NY, USA), and 100 μg/
ml streptomycin (Gibco, NY, USA) at 37°C in 5% CO2, as
recommended by Cellutions Biosystems Inc. Each vector
was transiently transfected into NSC34 cells using
Lipofectamine 2000 (Invitrogen, NY, USA). Approximately
80% of plated cells were transfected using our experimen-
tal procedures. For BV (Sigma, MO, USA) treatment,
BV solubilized with normal saline treated with transfected
cells by 2.5 μg/ml.
Proteasome activity assay
Cells were lysed using RIPA lysis buffer (50 mM Tris–HCl
pH 7.4, 1% NP-40, 0.1% SDS, and 150 mM NaCl) and the
Complete Mini Protease Inhibitor Cocktail (Roche, Basel,
Switzerland) and centrifuged at 14,000 rpm at 4°C for
20 min. The supernatant fraction was collected in a new
tube, and the protein concentration was determined using
a BCA protein kit (Interchim, Paris, France). The pro-
teasomal activity was measured using the 20S Proteasome
Activity Assay kit according to the manufacturer’s instruc-
tions (Chemicon Inc., CA, USA). The fluorescence of each
sample was evaluated with a spectrofluorometer at excita-
tion and emission wavelengths of 370 nm and 430 nm,
respectively. The level of proteasomal activity was deter-
mined from the increase in the fluorescence of the reac-
tion products.
SOD1 aggregation assay
For the SOD1 aggregation assay, 5 × 105 NSC34 cells were
plated on a cover slip and transfected using Lipofectamine
2000 (Invitrogen, NY, USA) for 48 hrs. The cells were
fixed with 4% paraformaldehyde for 10 min at room
temperature and then washed two times with phosphate-
buffered saline. The cover slip was fixed on a glass slide
using Fluoromount containing DAPI. Transfected cells
were observed using an Olympus fluorescent micros-
cope (Olympus, Tokyo, Japan) under identical exposure
settings.
For quantification of aggregated cells, 10 microscopic
visual fields were randomly selected and aggregated cells
including scattered filamentous or condensed forms
among GFP-positive cells were counted. The % aggrega-
tion was the percentage of aggregated cells among the
GFP-positive cells which transfected cells.
Immunoblotting and immunoprecipitation
Cell lysates were extracted using ice-cold lysis buffer
containing 50 mM Tris HCl pH 7.4, 1% NP-40, 0.1% SDS,
150 mM NaCl, and the Complete Mini Protease Inhibitor
Figure 1 BV treatment restores proteasome activity. NSC34 cells
(2 × 106) were transfected with GFP, GFP-hSOD1 or GFP-hSOD1G85R
constructs for 48 hrs and then treated with 2.5 μg/ml BV or equal
volume of saline for 24 hrs prior to being lysed. The proteasome
activity of the lysates was assayed using the 20S Proteasome Activity
Assay kit. Proteasome activity was significantly decreased in NSC34
cells that transiently overexpressed the mutant G85R SOD1
compared with the control. BV treatment increased proteasome
activity. The values shown are the means ± SEM of data obtained
from three independent experiments. * p < 0.05. BV; bee venom.
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tration was determined using a BCA Protein Assay Kit
(Pierce, IL, USA). Total cell lysates were immuno-
precipitated with an anti-GFP antibody overnight. After
incubating with protein A/G plus agarose beads, the
immunocomplex-beads were washed with RIPA buffer.
Boiled cell lysates (20 μg total protein per lane) or
immunocomplexes were subjected to SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) and transferred to nitro-
cellulose membranes (Whattman, Kan, USA). The mem-
branes were blocked in blocking solution (5% skim milk)
and incubated with primary antibodies against the follow-
ing proteins: α-tubulin (1:5000, Abcam, MA, USA), GFP,
GRP78 (1:1000, Santa Cruz Biotec, CA, USA), ISG15
(1:500, Santa Cruz Biotec, CA, USA), LC3 (1:1000, sigma,
MO, USA), and ubiquitin (1:2,000, DAKO, Denmark).
The membranes were incubated with a horseradish perox-
idase (HRP)-conjugated secondary antibody for 2 hrs at
room temperature. Specific protein bands were detected
with the SuperSignal West Femto Chemiluminescent Sub-
strate (Pierce, IL, USA) or enhanced chemiluminescence
reagents (Amersham Pharmacia, NJ, USA). α-tubulin was
used as an internal control for protein loading. Protein
bands were detected and analyzed using a FusionSL4-
imaging system. Quantification of the immunoblotted
bands was performed using the Bioprofil (Bio-1D version
15.01, Viber Lourmart).
SOD1 polymerization
To analyze SOD1 polymerization, 15 mg of fresh cells
was homogenized in 200 μl homogenizing buffer (50 mM
HEPES, 1 mM EDTA, 100 mM idoacetamide), incubated
at 37°C for 1 hrs and then centrifuged at 20,000 g for
5 min. The pellets were washed three times with a
washing buffer (50 mM HEPES, 1 mM EDTA, 100 mM
idoacetamide and 0.1% Nonidet P-40, pH 7.2) and
centrifuged at 20,000 g for 10 min. The final pellet (the
insoluble fraction) was suspended in 200 μl of final so-
lution A (50 mM HEPES, 1 mM EDTA, 100 mM
idoacetamide, and 2.5% sodium dodecyl sulfate (SDS),
pH 7.2). The insoluble fraction of each sample was
either treated with β-mercaptoethanol or left untreated
before boiling and then run through a 15% SDS
polyacrylamide gel for western blot analysis using an
antibody against misfolded hSOD1 (Medimabs, Quebec,
Canada).
Statistical analysis
For the comparisons between experimental groups, the
significant differences were analyzed by one-way ANOVA
using the PRISM program (GraphPad). The data are
expressed as the means ± S.E.M; p < 0.05 was considered
statistically significant.Results
BV treatment restored UPS function in hSOD1G85R-
expressing NSC34 motor neuron cells
A previous study showed that wild-type and mutant
hSOD1 were degraded by macroautophagy and the prote-
asome [3]. To investigate whether the overexpression of
hSOD1G85R in NSC34 motor neuron cells affects prote-
asome activity, 20S proteasome activity was examined.
Consistent with previous studies, hSOD1G85R overex-
pression in NSC34 cells suppressed proteasome activity
compared with GFP-transfected NSC34 cells (Figure 1).
However, treatment with 2.5 μg/ml BV for 24 hrs signifi-
cantly restored proteasome activity in hSOD1G85R-over-
expressing NSC34 motor neuron cells (Figure 1). These
data suggest that BV treatment improved the function of
the UPS in this mutant ALS cell model.BV treatment reduced the formation of ubiquitinated and
misfolded hSOD1G85R in NSC34 motor neuron cells
The overexpression of both wild-type and ALS-causing,
mutant hSOD1 led to the production of aggregates [18,19].
To determine whether BV treatment affects the aggregate
formation induced by mutant hSOD1G85R overexpression,
we counted the number of aggregates formed in the pres-
ence or absence of BV treatment for 48 hrs after transfec-
tion with either GFP-tagged wild-type or G85R mutant
hSOD1 in NSC34 motor neuron cells. We found that BV
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result of hSOD1G85R overexpression but that this reduction
was not statistically significant (Figure 2). Next, we investi-
gate whether BV treatment affect cell death by hSOD1G85R
overexpressed-aggregates in NSC34 cells. As shown in
Figure 2C, we did not observe significant cell death in
wild-type and G85R over expressed neuronal cells.
To confirm the effect of BV on aggregates resulting from
hSOD1G85R overexpression, we investigated the formation
of ubiquitinated or misfolded hSOD1G85R in NSC34 cells
in the presence or absence of BV treatment. As shown in
Figure 3A and D, the formation of ubiquitinated hSOD1G85R
and total ubiquitinated protein levels were significantly
reduced in BV treated hSOD1G85R-overexpressing NSC34
motor neuron cells. Furthermore, we also found that
misfolded SOD1 levels were reduced in these cells. These


















Figure 2 BV treatment does not significantly reduce the aggregation
G85R hSOD1-GFP construct for 24 hrs and then treated with 2.5 μg/ml BV
cells were fixed and immunofluorescent staining was performed with an a
a fluorescence microscope with fluoromount containing DAPI. Arrowheads
condensed aggregates. (B) Quantification of A. The values shown are the m
(bars, 25 μm.) * p < 0.05, ** p < 0.01. (C) Cells transfected with a WT or G85
saline for 24 hrs. Cell viability was measured with MTT assay.formation is correlated with a reduction in proteasome ac-
tivity and that BV treatment prevents the misfolding of
hSOD1G85R proteins and ameliorates the impairments in
UPS activity in mutant hSOD1-expressing motor neuron
cells.
BV does not activate the autophagic signaling pathway
Next, we investigated whether BV enhances the auto-
phagy signal pathway to eliminate the aggregates and
misfolded hSOD1G85R proteins in NSC34 cells. As
shown in Figure 4, hSOD1G85R overexpression induced
the expression of the microtubule-associated protein 1
light chain 3 II (LC3II) and ISG15 proteins compared
with the overexpression of GFP or wild-type hSOD1 in
NSC34 cells. However, BV treatment significantly re-
duced the expression of autophagosome-related pro-













of SOD1 protein. (A) Cells were transiently transfected with a WT or
or equal volume of saline for 24 hrs. At 48 hrs post-transfection, the
nti-GFP primary antibody. GFP-SOD1 aggregation was observed under
indicate scattered filamentous aggregates, and arrows indicate
eans ± SEM of data obtained from three independent experiments.





Figure 3 BV treatment reduces the accumulation of ubiquitinated and misfolded SOD1 proteins. After the transient transfection of NSC34
motor neuron cells with GFP or GFP-tagged hSOD1G85R for 24 hrs, cells were treated with 2.5 μg/ml BV or equal volume of saline for 24 hrs or
left untreated. The cells were lysed using RIPA buffer, immunoprecipitated with anti-GFP and then western blot analysis was performed using
primary anti-ubiquitin (A) and anti-GFP (B) antibodies. The arrowhead indicates GFP-tagged mutant hSOD1G85R. Total cell lysates were analyzed
by western blotting with anti-GFP (C) and anti-ubiquitin (D) primary antibodies. Asterisks indicate ubiquitinated proteins. To detect misfolded
SOD1, NSC34 cells transfected with wild-type or hSOD1G85R constructs were lysed using the SOD1 polymerization method described previously,
and an immunoblot analysis was performed with an anti-misfolded SOD1 antibody (E). The membranes were reprobed with an anti-tubulin
antibody as a loading control. G: GFP-transfected cells
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Figure 4 BV treatment does not activate the autophagic signal pathway. NSC34 cells were transiently transfected with the GFP control
vector or GFP-tagged wild-type hSOD1 or mutant hSOD1G85R. Approximately 24 hrs after transfection, the cells were treated with 2.5 μg/ml BV or
equal volume of saline for 24 hrs or left untreated. The cells were lysed using RIPA buffer, and western blot analysis was performed with anti-
GRP78, anti-LC3, and anti-ISG15 antibodies to examine the expression of autophagic-degradation proteins (A). The arrowhead indicates LC3II
protein levels. The membranes were reprobed with an anti-α-tubulin antibody as a loading control. Quantification of LC3II (B) and ISG15 (C) are
shown. The values shown are the means ± SEM of data obtained from three independent experiments. * p < 0.05, ** p < 0.01.
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cells. This result indicates that BV treatment improves
proteasome activity but not autophagosome activation in
mutant-hSOD1-overexpressing motor neuron cells.Discussion
ALS is often considered a proteinopathy because the gen-
eration of misfolded or abnormal proteins with the pro-
pensity to aggregate and accumulate in damaged neurons
is a common feature of both sporadic ALS (sALS) and
familial ALS (fALS) [6,20]. This study reveals that BV
treatment restores the proteasome activity inhibited by
hSOD1G85R expression and reduces the levels of misfolded
and ubiquitinated mutant SOD1 and aggregates in NSC34
motor neuron cells. BV treatment, however, did not affectthe autophagy endolysosomal pathway in hSOD1G85R-ex-
pressing motor neuron cells.
BV has been used in oriental medicine to reduce in-
flammation in rheumatoid arthritis and for the relief of
pain [21]. BV is composed of a variety of bio-active en-
zymes, different peptides and proteins, including melittin,
apamin, adolapin, mast cell degranulating peptide and
phospholipase A2 [22]. Melittin is a major component of
BV, and Yang et al. demonstrated that the administration
of melittin in an ALS animal model improved proteasome
activity and attenuated neuroinflammation in the spinal
cord and brainstem [23]. A previous study reported that
BV inhibits growth and exhibits cytotoxic effects in hepa-
tocellular carcinoma cells [24], and another study suggests
that BV induces pain and hyperalgesia [25]. Another
study, however, reported that BV reduces inflammatory
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more, BV has a protective role against 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-induced apoptosis in
neuronal cells [27] and diminishes neuroinflammation
in an MPTP-induced Parkinson animal model and an
hSOD1G93A-expressing ALS animal model [17,28].
Abnormally modified proteins and proteinaceous inclu-
sions can be found in most fALS and sALS cases. More-
over, these modified proteins are often components of the
inclusions in the motor neurons of not only patients but
also animal and cell models of the disease [29-31]. UPS,
which is the main intracellular proteolytic system, and the
autophagy-lysosome pathway are the predominant mecha-
nisms used to eliminate abnormal proteins and to degrade
cytoplasmic proteins; this degradation is mediated by
macroautophagy [32]. In ALS, mutant SOD1 is degraded
by proteasomes [33,34], and the partial inhibition of prote-
asome activity induces the formation of large SOD1-
containing aggregates [35,36]. When the proteasomes are
inhibited, the aggregates that significantly increase in size
and abundance become ubiquitinated, and this is accom-
panied by the formation of high-molecular-weight pro-
teins that represent the dimeric/oligomeric forms of
misfolded mutant SOD1 [37].
Changes in proteasome activity and the accumulation
of ubiquitinated protein aggregates have been demon-
strated in ALS patients and animal models [5,38,39]. In
this study, we found that the expression of mutant
hSOD1G85R reduced proteasome activity, which is con-
sistent with the findings of previous studies (Figure 1).
However, we did not observe that cell death by
overexpressing hSOD1G85R in NSC34 motor neuron cells
(Figure 2). Interestingly, BV treatment enhanced prote-
asome activity in GFP-hSOD1G85R-expressing motor
neuron cells compared with cells transfected with GFP
alone (Figure 1). Furthermore, we found that BV treat-
ment reduced the amount of ubiquitinated mutant SOD1
and misfolded SOD1 in hSOD1G85R-expressing NSC34
motor neuron cells (Figures 2 and 3).
However, BV consists of many enzymes, peptides and
proteins and melittin is a major component of BV. In pre-
vious study, we found that melittin treatment improved
proteasome acitivity in hSOD1G93A transgenic mice [23].
Therefore, we suggest that melittin from BV may be a bio-
active component in the improvement of proteasome ac-
tivity in GFP-hSOD1G85R-expressing motor neuron cells.
The ubiquitination and sumoylation of proteins are
mechanisms by which proteins are selectively targeted for
degradation, and this specificity is believed to be necessary
for the maintenance of cellular homeostasis [40]. Protein
sumoylation and ubiquitination are complex processes.
In many cases, including those in which a single
lysine is targeted, the two modifications do more than
simply antagonize or compete with each other [41]. Theubiquitination and sumoylation pathways often compete
with each other because the same lysine residue is fre-
quently used in both of their substrates. For example,
sumoylation of the pathogenic huntingtin fragment pre-
vents ubiquitination at the same lysine residue, which
abrogates proteasome-mediated degradation [42]. In this
study, we did not detect a significant reduction in the
number of SOD1-induced aggregates in BV-treated hS
OD1G85R-expressing NSC34 motor neuron cells (Figure 2),
even though the BV treatment decreased the formation of
ubiquitinated SOD1 (Figure 3). These results suggest that
the mutant SOD1 aggregates may contain sumoyla-
ted SOD1. Furthermore, Fei E et al. have shown that
hSOD1G85R sumoylation increases and may enhance the
stability of SOD1 [43]. It has been reported that the
sumoylation of the lysine residue of some proteins blocks
ubiquitination at the same site, which inhibits protein deg-
radation by the proteasome and alters protein function
[42,44].
Misfolded SOD1 has a toxic gain of function including
generation of reactive oxygen and nitrogen species [45],
and induction of mitochondrial dysfunction [46]. There-
fore, the research on consequent molecular pathway
mediated by misfolding SOD1 would be valuable for
finding the effective treatment for ALS patients.
Growing evidence supports a role for the autophagy
endolysosomal pathway in the pathogenesis of ALS.
Moreover, the accumulation of autophagosomes was ob-
served in the spinal cords of sporadic ALS patients [47],
indicating the presence of autophagic dysfunction in ALS.
Autophagic dysfunction results from defects in the initi-
ation (formation of autophagosomes) and/or maturation
stages of the autophagic process or an imbalance between
these stages. These conditions result in the aberrant accu-
mulation of misfolded and/or aggregated proteins within
the cells. In this study, BV treatment did not activate the
autophagic lysosomal pathway in hSOD1G85R-expressing
NSC34 motor neuron cells (Figure 4). This finding sug-
gests that BV treatment reduces the aggregation of pro-
teins specifically through ubiquitination and not activation
of the autophagy pathway.
It has been well established that cases of ALS associ-
ated with mutations in SOD1 are caused by the toxic
properties associated with the propensity of mutant
SOD1 to misfold [48,49]. Ubiquitinated, insoluble aggre-
gates are the pathological hallmark of several neurode-
generative diseases, including ALS, PD and AD. The
propensity for aggregate formation associated with
mutant SOD1 proteins, and the resulting toxic features,
may be related to the phenotypic expression of the
disease [2].
Currently, it is believed that a complex network incorp-
orating multiple toxicity pathways, rather than a single in-
dependent mechanism, is involved in the pathogenesis of
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stasis are of particular interest because the accumulation
of insoluble protein aggregates is the cardinal pathological
feature of ALS and other neurodegenerative diseases [50].
Although it remains to be determined whether such pro-
tein aggregates have a toxic or protective role in the
pathogenesis of ALS, it is possible that the formation of
aggregates results from an imbalance between the gener-
ation and degradation of misfolded proteins within
neuronal cells. Therefore, the solubility of hSOD1G85R
aggregates should be investigated to determine whether
insoluble proteins are associated with cell death in motor
neuron cells.
Conclusions
In this study, we have demonstrated the effects of BV on
the UPS impairments caused by hSOD1G85R overexpression
in motor neuron cells. The reduction in proteasome activity
may increase the number of mutant SOD1-positive aggre-
gates and induce SOD1 misfolding in mutant hSOD1-
expressing motor neuron cells.
BV treatment reduced the amount of ubiquitinated and
misfolded SOD1 in an in vitro ALS model. Although little
is known about the mechanisms by which BV affects pro-
teasome regulation, the findings of this study suggest that
BV should be considered as a candidate therapeutic agent
for regulating ALS pathological events.
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